A study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Trial Identifier: 222853
Sponsor: GlaxoSmithKline
Start Date: May 2024
Primary Completion Date: December 2024
Study Completion Date: June 2025
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, FL Hialeah, FL, United States, 33012
United States, FL Miami, FL, United States, 33147
United States, FL Miami, FL, United States, 33186
United States, IL Chicago, IL, United States, 60640
United States, IN Valparaiso, IN, United States, 46383
United States, KS El Dorado, KS, United States, 67042
United States, KS Lenexa, KS, United States, 66219
United States, KS Newton, KS, United States, 67114
United States, KS Wichita, KS, United States, 67207
United States, KY Lexington, KY, United States, 40509
United States, NC Greensboro, NC, United States, 27408
United States, NY Rochester, NY, United States, 14609
United States, TN Knoxville, TN, United States, 37909
United States, TX Austin, TX, United States, 78705
United States, TX Fort Worth, TX, United States, 76135
United States, TX Tomball, TX, United States, 77375
United States, VA Newport News, VA, United States, 23606
United States, VA Norfolk, VA, United States, 23502